Targeted Therapies
CIS BIOPHARMA’s innovative therapeutic modalities harness high-affinity antibodies and nanobodies to precisely deliver cytotoxic payloads to cancer cells, minimizing damage to healthy tissues. Our approach leverages the differential expression of tumor-associated antigens, CD 171 and CD 276, to achieve targeted drug delivery with enhanced specificity. This strategy shows exceptional promise in malignancies with historically poor prognoses and limited therapeutic options.
Antibody-drug conjugates, ADCs - History and Development
the first ADC was approved
0
by the US FDA for the treatment of acute myeloid leukemia, marking the dawn of a new era in cancer therapy.
five new ADCs entered
0
the market, a landmark year highlighting a period of rapid advancement and clinical validation of ADCs.
a total of fourteen ADCs
0
are FDA-approved, being at the forefront of clinical oncology and transforming cancer treatment paradigms.
Antibody-Drug Conjugate
ADC targeting CD 171
The lead program, CBO-001, comprises our proprietary antibody-drug conjugate targeting CD 171, L1CAM. This antigen plays a key role in oncogenesis, correlating strongly with tumor progression and metastasis. Its abundant expression across multiple solid tumors makes it an ideal target for delivering potent therapeutic payloads, including topoisomerase-I-inhibitors or radionuclides. L1CAM's overexpression in aggressive malignancies such as lung, breast, ovarian, and colorectal cancers positions CBO-001 as a potential game-changer in oncology.
Nanobody-Drug Conjugate
NDC targeting CD 276
Our innovative programs, CBO-002 and CBO-003, leverage advanced nanobody technology targeting CD 276, B7H3. These nanobodies, one-tenth the size of conventional antibodies, offer superior tumor penetration and rapid accumulation in target tissues. B7H3, highly overexpressed in differentiated malignant cells, promotes tumor migration, invasion, angiogenesis, and chemoresistance. Its widespread presence in various cancer malignancies, including brain metastases and glioblastoma multiforme, GBM, makes it an exceptional target. The nanobodies are engineered to deliver precision therapies, including topoisomerase-I-inhibitors or radionuclides, potentially revolutionizing brain tumor treatment.
CBO-001 targeting
lung cancer, SCLC
Our lead program offers renewed hope for patients facing incurable lung cancer, specifically the highly aggressive small cell lung cancer, SCLC.
This advanced antibody-drug conjugate, ADC, targets CD 171, also known as L1 surface molecule. The proprietary monoclonal antibody comprises state-of-the-art topo-isomerase-I-inhibitors attached by cleavable linkers.
CBO-002 targeting
brain metastases, BM
CBO-002 is engineered to overcome the limitations of cancer therapies in treating brain metastases, primarily associated with lung and breast cancers.
This innovative nanobody-drug conjugate, NDC, targets CD 276, also known as B7H3 surface molecule. The proprietary nanobody comprises state-of-the-art topo-isomerase-I-inhibitors attached by cleavable linkers.
CBO-003 targeting
glioblastoma, GBM
CBO-003 is designed to overcome the defense mechanisms of glioblastoma multiforme, GBM, an aggressive primary brain tumor with unmet need.
This novel nanobody-radionuclide conjugate or radioligand therapy, RLT, targets CD 276, also known as B7H3 surface molecule. The nanobody comprises state-of-the-art radionuclides attached by DOTA chelators.
